Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David H Vesole

Showing results (31-40 of 148) with videos related to

Pageof 15
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|November 12, 2013
Subepithelial corneal immunoglobulin deposition as a manifestation of multiple myeloma: a case report and literature reviewTrent P Wang, Steven G Safran, Joshua R Richter, et al.
Journal of the National Cancer Institute|June 19, 2009
Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysisSergio Giralt, David H Vesole, George Somlo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 11, 2016
Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple MyelomaTulio E Rodriguez, Parameswaran Hari, Patrick J Stiff, et al.
Advances in Clinical and Experimental Medicine : Official Organ Wroclaw Medical University|March 10, 2018
Blocking MET receptor signaling in multiple myeloma cells in vitro and in vivoArtur Jurczyszyn, Anna Zebzda, Joanna Gdula-Argasińska, et al.
Mayo Clinic Proceedings|July 14, 2006
High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research StudyDavid H Vesole, Waleska S Pérez, Marwan Akasheh, et al.
Blood Advances|February 17, 2026
Vestibular Symptoms Following Talquetamab Therapy in Heavily Pretreated Multiple MyelomaJames Di Palma-Grisi, Noa Biran, Pooja Phull, et al.
Leukemia & Lymphoma|September 17, 2004
Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98)Morie A Gertz, Montserrat Rue, Emily Blood, et al.
Annals of Hematology|April 24, 2023
Hospital facility characteristics and socioeconomic factors on outcomes and treatment in patients with multiple myeloma: National Cancer Database analysisKimberley Doucette, Allison O Taylor, Bryan Chan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 13, 2009
A Phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97David H Vesole, Lijun Zhang, Neal Flomenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2020
Treatment of Smoldering Myeloma: Problems With Study Design as well as Biological and Clinical ImplicationsNoa Biran, David H Vesole, Michele L Donato, et al.
Pageof 15

Showing results (31-40 of 148) with videos related to

Sort By:
Pageof 15
Clinical Lymphoma, Myeloma & Leukemia|November 12, 2013
Subepithelial corneal immunoglobulin deposition as a manifestation of multiple myeloma: a case report and literature reviewTrent P Wang, Steven G Safran, Joshua R Richter, et al.
Journal of the National Cancer Institute|June 19, 2009
Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysisSergio Giralt, David H Vesole, George Somlo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 11, 2016
Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple MyelomaTulio E Rodriguez, Parameswaran Hari, Patrick J Stiff, et al.
Advances in Clinical and Experimental Medicine : Official Organ Wroclaw Medical University|March 10, 2018
Blocking MET receptor signaling in multiple myeloma cells in vitro and in vivoArtur Jurczyszyn, Anna Zebzda, Joanna Gdula-Argasińska, et al.
Mayo Clinic Proceedings|July 14, 2006
High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research StudyDavid H Vesole, Waleska S Pérez, Marwan Akasheh, et al.
Blood Advances|February 17, 2026
Vestibular Symptoms Following Talquetamab Therapy in Heavily Pretreated Multiple MyelomaJames Di Palma-Grisi, Noa Biran, Pooja Phull, et al.
Leukemia & Lymphoma|September 17, 2004
Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98)Morie A Gertz, Montserrat Rue, Emily Blood, et al.
Annals of Hematology|April 24, 2023
Hospital facility characteristics and socioeconomic factors on outcomes and treatment in patients with multiple myeloma: National Cancer Database analysisKimberley Doucette, Allison O Taylor, Bryan Chan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 13, 2009
A Phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97David H Vesole, Lijun Zhang, Neal Flomenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2020
Treatment of Smoldering Myeloma: Problems With Study Design as well as Biological and Clinical ImplicationsNoa Biran, David H Vesole, Michele L Donato, et al.
Pageof 15